January 2020

Reduced Research & Development (R&D) productivity, as well as patent expiries and advances in technology, has led to significant changes for the pharmaceutical industry. Leading life sciences firms are not only being forced to look closely at the scale and cost of their property portfolios but also question whether they are located in the best environment to access innovation and talent. Real estate in the life science industry is moving from being an operational necessity to a source of competitive advantage.